Sequenom to Issue More Shares of Stock to SensiGen Shareholders; Settles Claims | GenomeWeb

NEW YORK (GenomeWeb News) - Sequenom said after the close of the market yesterday that it has agreed to issue additional shares to shareholders of SensiGen to settle certain claims asserted following Sequenom's purchase of SensiGen's assets.

According to a filing with the US Securities and Exchange Commission, Sequenom will issue to certain stockholders 367,547 shares of its common stock. In July, those shareholders had asserted claims for damages of around $1.3 million from an alleged breach of representations and warranties made by Sequenom in its asset purchase agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.